Skip to content

The Salt Study for Heart Failure

Evaluating Effect of Low-Sodium and Regular Diets on Heart Failure Outcomes

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07560592
Enrollment
500
Registered
2026-05-01
Start date
2026-01-21
Completion date
2028-11-01
Last updated
2026-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Keywords

Heart failure, Salt diet

Brief summary

The purpose of this study is to understand if low sodium (cardiac) diet is indeed necessary for better health outcomes in patients who suffered heart failure. This study will investigate the association between sodium intake and risk for 30-day re-admission in Heart Failure (HF) patients.

Interventions

OTHERNormal Salt Diet

This study will allow regular diet 3-4 g Na-Salt per day in patients with acute HF as an intervention, because the standard recommendation for such patients is cardiac diet with 2 g Na per day. The intervention will end when the patient is discharged from the hospital. They will follow routine clinical care recommendations after discharge from hospital.

OTHERCardiac Diet

This arm of study will allow the cardiac diet with 2 g Na per day, that is standard recommendation for HF patients. They will follow routine clinical care recommendations after discharge from hospital.

Sponsors

Maya Guglin, MD
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Intervention model description

All patients with study ID ending in an odd number will be randomized to the Cardiac diet (control arm) and even number to the normal diet (interventional arm).

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Above 18 years of age * Hospitalization due to Heart Failure admitted within 24 hours

Exclusion criteria

* Concomitant hypertension (blood pressure \>150/90 mmHg on admission) * End stage renal disease (on hemodialysis or peritoneal dialysis * Cardiogenic shock

Design outcomes

Primary

MeasureTime frameDescription
Length of hospital stayHospital admission to time of discharge assessed up to 1 yearnumber of days the patient remains hospitalized
30-day readmission30 days after discharge from hospital after index eventreadmission to hospital within 30 days of discharge from the index event
NT-proBNP on dischargetime of hospital admission to 30 days after dischargeMeasurement of blood levels of NT-ProBNP a biomarker for diagnosing and assessing the severity of heart failure.
Loop diuretic requirement during index admissiontime of hospital admission to 30 days after dischargeFurosemide, torsemide, and bumetanide are specific loop diuretics used in the treatment of fluid overload / retention conditions like congestive heart failure.

Countries

United States

Contacts

CONTACTMaya Guglin, MD
maya.guglin@rutgers.edu8483915776
CONTACTManisha Bajpai, PhD
manisha.bajpai@rutgers.edu
PRINCIPAL_INVESTIGATORMaya Guglin, MD

Rutgers University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 2, 2026